See more news releases in Health Care & Hospitals | Infection Control | Medical Pharmaceuticals | Surveys, Polls and Research | Trade Show

MedImmune To Present Three Influenza Abstracts At The IDWeek 2012 Meeting

GAITHERSBURG, Md., Oct. 19, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced today it will present three influenza abstracts at IDWeek 2012: the first combined meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society, in San Diego, California, October 17-21, 2012. These abstracts expand upon the existing body of knowledge and data around flu vaccination, highlighting MedImmune's continued dedication to exceptional science, innovation, and patient health.

MedImmune flu abstracts to be presented at IDWeek 2012 include:

Cost-Effectiveness of Live Attenuated Influenza Vaccine Versus Inactivated Influenza Vaccine Among Children Aged 2-17 Years for Mild, Moderate and Severe Influenza Seasons. Ryan KJ, et al. Poster Session: Saturday, October 20, 2012, Time: 12:30 PM - 2:00 PM, Location: Halls F-H.
The Role of Nasal IgA in Children Vaccinated With Live Attenuated Influenza Vaccine. Ambrose CS, et al. Poster Session: Saturday, October 20, 2012, Time: 12:30 PM - 2:00 PM, Location: Halls F-H.
The Safety and Effectiveness of Self-Administration of Intranasal Live Attenuated Influenza Vaccine in Adults. Ambrose, CS, et al. Poster Session: Saturday, October 20, 2012, Time: 12:30 PM - 2:00 PM, Location: Halls F-H.

Additional information about IDWeek 2012 can be found at http://www.idweek.org/.

About MedImmune
MedImmune, the global biologics arm of AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune